Zepbound Vials vs Pens

In 2024, Eli Lilly, the manufacturer of the weight-loss medication Zepbound (tirzepatide), announced that it would offer the drug in single-dose vials at a lower price than the prefilled injector pens many patients use. These weekly dose vials differ from the preloaded pens used for Zepbound and similar to GLP-1 medications such as Wegovy (semaglutide).

This option can reduce monthly costs, but it also requires more preparation and comfort with manual injections.

The right format is the one you can use consistently without hesitation. Below, we explain how Zepbound pens and vials differ in everyday use and which option may be the better fit depending on your needs.

How the Zepbound Pen and Vial Work

The Zepbound pen is a prefilled, single-dose device designed to deliver one full weekly dose per pen. Each pen is color-coded by strength, so there is no need to measure or prepare the medication before injecting.

When it is time for your dose, you simply remove the cap, place the pen against your skin, press the button, and wait until the indicator confirms the injection is complete. Once used, the pen is discarded in a sharps container.

Because the dose is premeasured and the steps are limited, the pen format keeps the weekly injection process simple and consistent.

Using a Zepbound vial requires more hands-on preparation. The process involves attaching a needle to a sterile syringe, drawing the prescribed amount of medication from the vial, and carefully removing air bubbles before injecting.

This method takes more time and requires close attention to dose measurement to ensure accuracy.

Fun fact!

Outside the US, Zepbound is available in a different pen format called the Zepbound KwikPen. Unlike the single-dose pens, the KwikPen is a multi-dose, single-patient-use prefilled pen.

Each Zepbound KwikPen contains four fixed weekly doses, with each injection delivering 0.6 mL of tirzepatide under the skin. The pen is available in six different strengths, covering the full dosing range from starter doses to higher maintenance doses.

Comparing Zepbound Vials vs. Pens

Both formats deliver the same medication and work the same way inside the body. Most of the difference is in user experience. These include:

1. Steps and complexity

Pens reduce steps, and fewer steps generally mean fewer opportunities to make a mistake, especially when you are new to injections or anxious. For the vial, you must reliably do all of the following:

• • Attach the needle to the syringe
  • Pull air into the syringe
  • Inject air into the vial
  • Draw liquid to the correct line
  • Remove air bubbles and reset the plunger to the correct line
  • Inject, then safely dispose

If you are new to injectable medications, you may find the pen easier to use because it involves fewer steps. Its simple push-button design can also be helpful if you have mild vision changes or minor hand or finger stiffness.

In 2015, researchers looked at how people use the liraglutide pen (Saxenda), including people with and without injection experience. Participants were asked to complete six common tasks, such as:

• • Picking the correct medication box and pen
  • Checking the liquid inside the pen
  • Performing a normal injection
  • Correcting a dose if they turned the dial too far
  • Recognizing when the pen was empty

After each task, participants were interviewed about difficulty, confusion, or mistakes. Those who received even brief training made fewer errors and had fewer close calls, no matter whether they had injected medications before.

The pen design also worked well, and users found the pen easy to use. Participants rated the pen 6.4 out of 7 for ease of use, which is very high.

In another study, the dulaglutide pen (Trulicity), which uses a pen mechanism similar to Zepbound, was associated with higher user satisfaction and stronger preference ratings compared with other GLP-1 receptor agonist pen devices.

2. Dose accuracy and dosing errors

Zepbound is a titrated medication, which means the dosage is gradually increased over time to optimize effectiveness while minimizing potential side effects, like nausea and vomiting.

The pen format supports consistent dosing because the manufacturer pre-measures the exact weekly dose. This helps keep each injection consistent, with very little chance of getting more or less medication than intended.

If you use a single-dose vial, the vial still contains only one dose, but you measure the medication yourself when drawing it into the syringe. Even small measuring differences can result in getting slightly more or slightly less medication than prescribed.

This is especially important considering that the FDA has received 545 reports of adverse events associated with compounded tirzepatide, which requires syringe injections.

3. Convenience, adherence, and persistence

Real-world and observational literature in diabetes care has often found better satisfaction and, in some settings, better adherence with pens compared with vial and syringe regimens, largely because pens are more convenient.

In one study, people who had never handled insulin before said the pen was much easier and less confusing than drawing insulin from a vial with a syringe. When asked which method they would rather use, most participants chose the pen.

When using a pen, the dose delivered was also closer to the intended amount. With vials and syringes, doses varied more. This was true for both those experienced with insulin and those completely new to insulin.

In another study, patients using pens missed fewer doses and stayed on treatment longer. This suggests pens may make it easier to follow long-term therapy.

4. Cost

According to Eli Lilly’s pricing page, the list price of a 4-pen Zepbound package is $1,086.37 per 28 days. If you don’t have commercial insurance, you can expect to pay close to this price, plus any additional pharmacy charges, depending on where you purchase your medicine.

By comparison, Zepbound single-dose vials are offered in a 4-count package at the following direct-to-patient price:

If your insurance covers Zepbound, the pen may be the better option because it is easier to use, delivers consistent dosing, and keeps out-of-pocket costs manageable. In this situation, price is usually not a limiting factor.

If you do not have insurance coverage or access to savings programs that reduce the cost of Zepbound, long-term affordability can become a concern. In that case, the vial option may provide a more sustainable and affordable way to stay on treatment over time.

5. Accessibility

Beyond price, accessibility matters just as much. Zepbound is intended for long-term use, so it is important to choose an option you can reliably obtain each month. Interrupting treatment may lead to weight regain.

Zepbound pens are widely stocked at retail pharmacies. They have been available since 2022, and earlier supply constraints have largely been addressed, making monthly access more predictable for many patients.

Zepbound vials, by contrast, were introduced in August 2024 and are currently available only through LillyDirect Self Pay Pharmacy Solutions. Access may involve mail delivery or a limited number of pickup locations, depending on your region, which can affect how quickly and consistently you receive refills.

6. Safety considerations

Both the Zepbound pen and vial are FDA-approved and meet safety standards for sterility, needle quality, and accurate dose delivery.

If you use the pen, the risk of user error is lower. The needle is built into the device and stays hidden during handling. Once the pen is activated, it cannot be reused, which helps reduce contamination. Many people also feel less anxious using the pen because they never see or handle the needle directly.

If you use the vial, sterility requires more active care on your part. Each additional step in injecting increases the chance that bacteria could be introduced if aseptic technique is not followed closely. Touching the needle, contaminating the vial opening, or placing supplies on non-sterile surfaces can raise infection risk.

Another safety concern with the vial format is that it allows for microdosing. GLP-1 microdosing refers to the off-label practice of injecting smaller-than-standard amounts of GLP-1 medications in an effort to reduce side effects such as nausea or constipation while still suppressing appetite.

While this may sound appealing, microdosing introduces several risks. You may receive doses that are not supported by clinical trials, which means the safety and effectiveness of those amounts are unknown.

Inconsistent exposure to the medication can also lead to unpredictable effects. In some cases, microdosing may delay proper dose escalation, reduce treatment effectiveness, or encourage unsupervised dose experimentation without medical guidance.

7. Storage and handling

Proper storage is essential for both safety and medication stability.

Both Zepbound pens and vials must be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) before use. According to FDA labeling, either format may be kept at room temperature up to 86°F (30°C) for a maximum of 21 days once removed from refrigeration. During this period, the medication should be protected from direct sunlight and heat.

If a pen or vial is left out longer than 21 days or exposed to temperatures above 86°F, it should be discarded and not used.

Because the vial requires additional supplies, storage safety extends beyond the medication itself. Syringes and needles should be kept in their original sterile packaging, stored at room temperature, and protected from moisture, dust, and contamination.

You should not store loose needles or syringes in bags, drawers, or bathrooms where humidity and bacteria are more likely. Any syringe or needle that has been opened, dropped, or touched should be discarded, even if it was not used.

While the vial format does not change how tirzepatide behaves chemically, managing multiple components increases the number of items that must be stored correctly. Pens reduce this burden by keeping the needle and medication sealed together until use.

How To Decide Which Is Better For You

To help you decide, here is a summary of a patient discussion comparing experiences with Zepbound pens and vials.

The original poster asked the r/Zepbound community to explain the practical benefits of using Zepbound pens versus single-dose vials. They also asked whether syringes are provided when ordering vials.

Cost differences drive most decisions

Many commenters explained that the primary advantage of vials is lower out-of-pocket cost. Several people pointed out that vials are especially appealing for those who do not qualify for insurance coverage or Lilly’s savings programs, including people on certain government plans or without commercial insurance.

In contrast, commenters explained that pens can be much more affordable for people whose insurance covers them. One user described paying a very low monthly cost after meeting their deductible and combining insurance coverage with manufacturer savings programs. For those users, pens were clearly the better option financially.

Several commenters emphasized that when insurance or savings cards apply, the price gap between pens and vials narrows significantly. When paying fully out of pocket, the gap becomes much larger in favor of vials.

Convenience versus control

A consistent theme was that pens are favored for simplicity. People described pens as easier to inject, easier to store, easier to travel with, and less mentally demanding. Some commenters said they preferred pens because dosing is premeasured and there are fewer steps each week.

On the other hand, people who preferred vials often described liking the sense of control. They appreciated drawing the medication themselves, choosing how quickly to inject, and having flexibility with syringes. Several people said vials felt familiar if they had prior experience with injectable medications.

One commenter openly described themselves as detail-oriented and said that preference made vials more appealing than pens.

Syringes and supplies

Several commenters addressed the question about syringes directly. They explained that when ordering vials through LillyDirect, patients are typically offered a syringe kit for a small additional cost. Some reported that syringes and alcohol wipes were sometimes included even if not explicitly purchased, though this was inconsistent.

Because of that uncertainty, many people recommended having a backup plan by purchasing insulin syringes independently from a local pharmacy or online. A few users mentioned choosing slightly larger syringes to make dose measurement easier.

Alcohol wipes were described as inexpensive and easy to source.

Perceived dosing differences and effectiveness

Toward the end of the thread, one user asked whether switching from pens to vials affected appetite suppression, noting that they had seen reports suggesting reduced effectiveness.

A reply explained that one person experienced weaker effects and fewer side effects during their first week on vials, but those effects returned the following week. They suspected user error, injection placement issues, or timing disruptions rather than a true difference in medication. The commenter emphasized that the drug itself is the same in both formats.

This part of the discussion suggested that perceived differences are likely due to technique, timing, or expectations rather than formulation.

Bottom Line

Both formats contain the same medication and provide the same clinical results when used correctly. The decision depends on comfort, convenience, and experience. The pen is the simplest option and suits those who want a quick, predictable weekly routine. The vial works well for people comfortable with syringes or manual injections.

The best format is the one that helps you stay consistent and avoid errors. If you are unsure which format suits you best, a healthcare provider can help guide the decision. They can consider your comfort level with injections, prior experience, insurance coverage, and how each option fits into your weekly routine.

Frequently Asked Questions

Sources

Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lilly-releases-zepboundr-tirzepatide-single-dose-vials-expanding

Slabaugh, S. L., Bouchard, J. R., Li, Y., Baltz, J. C., Meah, Y. A., & Moretz, D. C. (2015). Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes. Advances in Therapy, 32(12), 1206–1221. https://doi.org/10.1007/s12325-015-0266-5

FDA. (2025, September 25). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food And Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Asakura, T., Seino, H., Nakano, R., Muto, T., Toraishi, K., Sako, Y., Kageyama, M., & Yohkoh, N. (2009). A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technology & Therapeutics, 11(10), 657–661. https://doi.org/10.1089/dia.2009.0006

Lasalvia, P., Barahona-Correa, J. E., Romero-Alvernia, D. M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J. G., Triana, J. J., Laserna, A. F., Mejía-Torres, M., Restrepo-Jimenez, P., Jimenez-Zapata, J., & Rosselli, D. (2016). Pen Devices for Insulin Self-Administration Compared With Needle and Vial. Journal of Diabetes Science and Technology, 10(4), 959–966. https://doi.org/10.1177/1932296816633721

Fujioka, K., Sparre, T., Sun, L. Y., Krogsgaard, S., & Kushner, R. F. (2015). Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience. Journal of Diabetes Science and Technology, 10(1), 164–174. https://doi.org/10.1177/1932296815593295

Zepbound Cost Information | With or Without Insurance | Zepbound® (tirzepatide) injection. (n.d.). https://pricinginfo.lilly.com/zepbound

Zhou, A. Y., & Trujillo, J. M. (2018). Comparison of usability, accuracy, preference, and satisfaction among three Once-Weekly GLP-1 Receptor Agonist PEN devices. Diabetes Spectrum, 31(4), 359–366. https://doi.org/10.2337/ds17-0048